Search
calcium phosphate product (Ca-P product)
Reference interval:
- < 55 mg2/dL2 [1]
- serum Ca+2 (albumin-corrected) x serum phosphate product < 4 mmol/L
Clinical significance:
- of importance in stage 5 kidney disease
- high calcium phosphate product in plasma, increases risk of soft-tissue calcification (calciphylaxis)
- calcium-phosphate product of > 55 (mg/dL)2 associated with acute or subacute calcification of vascular, cardiac, & other soft tissues
- since many factors are involved in the genesis of soft-tissue calcification, no exact threshold for the calcium phosphate product predicts soft-tissue calcification
- hypercalcemia, together with hyperphosphatemia, or each individually can be responsible for increased plasma calcium phosphate product
- since serum phosphate levels in patients with chronic kidney disease are usually increased by more (from 3.5 mg/dL to 7 mg/dL) than serum calcium (from 9.5 mg/dL to 11 mg/dL, the relative importance of serum phophate levels in generating higher calcium phosphate product is greater than serum calcium levels
- thus control of calcium phosphate product is best achieved by controlling levels of serum phosphate
Increases:
- risk of soft-tissue calcification (calciphylaxis)
General
general chemistry test
References
- NKF KDOQI GUIDELINES
National Kidney Foundation
http://www.kidney.org/professionals/kdoqi/guidelines_bone/Guide6.htm